Case Western Reserve, Lucid Diagnostics sign agreement on Barrett's Esophagus detector

CLEVELAND–Case Western Reserve University and Lucid Diagnostics, a subsidiary of publicly traded New York-based medical device company, PAVmed Inc. (Nasdaq: PAVM), have signed an exclusive license agreement to commercialize a technology that quickly and accurately detects Barrett’s Esophagus, the primary precursor of esophageal cancer.

The technology, called EsoCheck, combines a non-invasive, cell-sampling device with highly accurate DNA biomarkers to detect the condition.

The company is based on discoveries by three scientific founders: Sanford Markowitz, the Markowitz-Ingalls Professor of Cancer Genetics and Distinguished University Professor at Case Western Reserve and medical oncologist at University Hospitals Seidman Cancer Center; Amitabh Chak, professor of medicine at Case Western Reserve School of Medicine, gastroenterologist at University Hospitals Digestive Health Institute and director of the Advanced Technology and Innovation Center of Excellence at University Hospitals Division of Gastroenterology; and Joseph Willis, professor of pathology and pathology vice chair for clinical affairs at University Hospitals Cleveland Medical Center.

“This is an exciting opportunity to bring a basic medical discovery forward into the clinic, to benefit patients, to prevent a deadly disease and to save lives,” Markowitz said.

“We believe EsoCheck has the potential to replicate the impact of Pap screening for cervical cancer and colonoscopy screening for colon cancer in


Article originally posted at

Click here for the full story


Privacy Policy / Terms Of Use

       Powered by MMD